Deutsche Bank's research report on GlaxoSmithKline (GSK) maintains a 'Hold' rating, highlighting the company's decision to forgo a £4bn B share scheme in favor of maintaining dividends. The report discusses revised forecasts due to margin resets and cost-saving programs, with a focus on execution and investor confidence. The target price is adjusted from 1,600p to 1,540p, reflecting potential EPS growth and dividend yield.
documents/vol00010-efta01457557-pdf.pdf
{"title":"Deutsche Bank Markets Research - GlaxoSmithKline","key_people":["Richard Parkes","Tim Race"],"document_date":"2015-05-11","document_type":"tabular","key_locations":["United Kingdom"],"document_subtype":"financial report","key_organizations":["Deutsche Bank","GlaxoSmithKline"]}